Provigil Antitrust Cert. Bid Doomed By Inability To ID Class

By Melissa Lipman (June 11, 2015, 7:33 PM EDT) -- A Pennsylvania federal judge on Wednesday explained that his recent refusal to let consumers and health plans go forward with class antitrust pay-for-delay claims against Cephalon Inc. and four generic drugmakers stemmed from concerns that the plaintiffs had no way to ascertain who the class members were....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!